Dosage form for treating cardiovascular diseases comprising isradipine

Claim 1

A method for treating a cardiovascular disease, wherein the method comprises: (A) admitting into a patient afflicted with a cardiovascular disease an osmotic dosage form comprising: (1) a wall comprising at least in part a composition permeable to the passage of fluid, which wall surrounds; (2) a compartment; (3) a first composition in the compartment, said first composition comprising from 2 milligrams to 30 milligrams of isradipine for treating a cardiovascular disease, from 30 weight percent to 95 weight percent of a polyethylene oxide comprising a molecular weight of from 100,000 to 300,000, and from 0 weight percent to 15 weight percent of a hydroxypropylmethylcellulose comprising a molecular weight of 9,000 to 15,000; (4) a second composition in the compartment, said second composition comprising from 55 weight percent to 70 weight percent of a polyethylene oxide comprising a molecular weight of from 5,000,000 to 7,800,000, from 15 weight percent to 30 weight percent of an osmotically effective solute, and from 5 weight percent to 15 weight percent of a hydroxypropylmethylcellulose comprising a molecular weight of 9,000 to 20,000 which second composition aid the dosage form in delivering the first composition from the compartment; (5) at least one passageway in the wall for delivering the isradipine from the dosage form; (B) letting fluid enter the dosage form for (a) contacting the first composition for providing a dispensable isradipine composition, and for (b) contacting the second composition for causing it to aid in delivering the first composition; thereby, (C) delivering through the combined operations of the first and second composition a therapeutically effective amount of isradipine to the patient for treating the cardiovascular disease.

Claim 2

A method for treating a cardiovascular disease, wherein the method comprises: (A) admitting into a patient afflicted with a cardiovascular disease an osmotic dosage form comprising: (1) a wall comprising at least in part a composition permeable to the passage of fluid, which wall surrounds; (2) a compartment; (3) a first composition in the compartment, said first composition comprising from 2 milligrams to 30 milligrams of isradipine for treating a cardiovascular disease, from 30 weight percent to 95 weight percent of a polyethylene oxide comprising a molecular weight of from 100,000 to 300,000, and from 0 weight percent to 15 weight percent of a hydroxypropylmethylcellulose comprising a molecular weight of 9,000 to 15,000; (4) a second composition in the compartment, said second composition comprising from 55 weight percent to 70 weight percent of a polyethylene oxide comprising a molecular weight of from 5,000,000 to 7,800,000, from 15 weight percent to 30 weight percent of an osmotically effective solute, and from 5 weight percent to 15 weight percent of a hydroxypropylmethylcellulose comprising a molecular weight of 9,000 to 20,000 which second composition aid the dosage form in delivering the first composition from the compartment; (5) at least one passageway in the wall for delivering the isradipine from the dosage form; (B) letting fluid enter the dosage form for (a) contacting the first composition for providing a dispensable isradipine composition, and for (b) contacting the second composition for causing it to aid in delivering the first composition; thereby, (C) delivering through the combined operations of the first and second composition a therapeutically effective amount of isradipine to the patient for treating the cardiovascular disease.